

# 1 Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection

2  
3 Oluwasanmi O. Adenaiye, M.B.B.S., M.S.<sup>a</sup>, Jianyu Lai, B.Med., M.P.H.<sup>b</sup>, P. Jacob Bueno de Mesquita,  
4 Ph.D.<sup>a</sup>, Filbert Hong, Ph.D.<sup>a</sup>, Somayah Youssefi, Ph.D.<sup>a</sup>, Jennifer German, Ph.D.<sup>a</sup>, S.-H. Sheldon Tai,  
5 Ph.D.<sup>a</sup>, Barbara Albert, M.D., M.P.H.<sup>a</sup>, Maria Schanz, B.A., B.S.<sup>a</sup>, Stuart Weston, Ph.D.<sup>c</sup>, Jun Hang,  
6 Ph.D.<sup>d</sup>, Christian Fung, M.S.<sup>d</sup>, Hye Kyung Chung, Ph.D.<sup>d</sup>, Kristen K. Coleman, Ph.D.<sup>e</sup>, Nicolae Sapoval,  
7 B.S.<sup>f</sup>, Todd Treangen, Ph.D.<sup>f</sup>, Irina Maljkovic Berry, Ph.D.<sup>d</sup>, Kristin Mullins, Ph.D.<sup>g</sup>, Matthew Frieman,  
8 Ph.D.<sup>c</sup>, Tianzhou Ma, Ph.D.<sup>b</sup>, Donald K. Milton, M.D., Dr.P.H.<sup>a</sup> for the University of Maryland  
9 StopCOVID Research Group<sup>\*</sup>

10  
11 <sup>a</sup> Public Health Aerobiology and Biomarker Laboratory, Institute for Applied Environmental Health,  
12 University of Maryland School of Public Health, College Park, Maryland, USA

13 <sup>b</sup> Department of Epidemiology and Biostatistics, University of Maryland School of Public Health,  
14 College Park, Maryland, USA

15 <sup>c</sup> Department of Microbiology and Immunology, University of Maryland School of Medicine,  
16 Baltimore, Maryland, USA

17 <sup>d</sup> Viral Diseases Branch, Walter Reed Army Institute for Research, Silver Spring, Maryland, USA

18 <sup>e</sup> Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore

19 <sup>f</sup> Department of Computer Science, Rice University, Houston, Texas, USA

20 <sup>g</sup> Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA

21  
22 <sup>\*</sup> Dr. Donald K. Milton, University of Maryland School of Public Health, 4200 Valley Drive, College  
23 Park, MD 20742 email: [dmilton@umd.edu](mailto:dmilton@umd.edu); phone: 301-405-0389 (Alternate: Dr. Filbert Hong, at the  
24 same address, email [fhong@umd.edu](mailto:fhong@umd.edu), phone: 301-405-4081)

25  
26 Key words: SARS-CoV-2; exhaled breath aerosol; face masks; airborne infection; SARS-CoV-2  
27 variants

28 Running Title: SARS-CoV-2 in Exhaled Aerosols

## 29 Key Points:

- 30 • Cases exhale infectious viral aerosols.
- 31 • SARS-CoV-2 is evolving toward more efficient airborne transmission.
- 32 • Loose-fitting masks significantly but moderately reduce viral RNA aerosol.
- 33 • Tight-fitting masks or respirators and ventilation/air cleaning are essential for worker protection  
34 in public-facing or crowded indoor workplaces.
- 35

38  
39

## 40 Abstract

41

42 **Background:** SARS-CoV-2 epidemiology implicates airborne transmission; mask source-control  
43 efficacy for, variant impact on, and infectiousness of aerosols are not well understood.

44 **Methods:** We recruited COVID-19 cases to give blood, saliva, mid-turbinate and fomite (phone) swabs,  
45 and 30-minute breath samples while vocalizing into a Gesundheit-II, with and without masks at up to  
46 two visits two days apart. We quantified and sequenced viral RNA, cultured virus, and assayed sera for  
47 anti-spike and anti-receptor binding domain antibodies.

48 **Results:** We enrolled 61 participants with active infection, May 2020 through April 2021. Among 49  
49 seronegative cases (mean days post onset  $3.8 \pm 2.1$ ), we detected SARS-CoV-2 RNA in 45% of fine ( $\leq 5$   
50  $\mu\text{m}$ ), 31% of coarse ( $> 5 \mu\text{m}$ ) aerosols, and 65% of fomite samples overall and in all samples from four  
51 alpha variant cases. Masks reduced viral RNA by 48% (95% confidence interval [CI], 3 to 72%) in fine  
52 and by 77% (95% CI, 51 to 89%) in coarse aerosols. The alpha variant was associated with a 43-fold  
53 (95% CI, 6.6 to 280-fold) increase in fine aerosol viral RNA that remained a significant 18-fold (95%  
54 CI, 3.4 to 92-fold) increase adjusting for viral RNA in saliva, in mid-turbinate swabs, and other potential  
55 confounders. Two fine aerosol samples, collected days 2-3 post illness onset, while participants wore  
56 masks, were culture-positive.

57 **Conclusion:** SARS-CoV-2 is evolving toward more efficient airborne transmission and loose-fitting  
58 masks provide significant but only modest source control. Therefore, until vaccination rates are very  
59 high, continued layered controls and tight-fitting masks and respirators will be necessary.  
60

## 61 Introduction

62  
63 The World Health Organization[1] and U.S. Centers for Disease Control and Prevention[2] recently  
64 acknowledged the growing scientific consensus that inhalation exposure is an important route of SARS-  
65 CoV-2 transmission[3,4]. The totality of evidence from epidemiologic and outbreak investigations,  
66 combined with data on the size distribution of exhaled aerosols and corresponding quantitative models,  
67 is compelling[4]. However, culture of the virus from exhaled aerosols, and direct measures of the  
68 efficacy of face masks as viral aerosol source control when worn by actual patients have been lacking.  
69 Previous reports of infectious virus[5,6] and viral RNA concentrations in room air[7,8] do not provide a  
70 clear picture of how much virus infected persons shed into the air. These gaps lead to uncertainty in  
71 estimates of exposure, derived from retrospective analysis of outbreaks[9]. New variants also appear  
72 more transmissible, but more quantitative data is needed to discern what that means for implementing  
73 effective non-pharmaceutical interventions – still a mainstay of infection protection.  
74

75 We collected exhaled breath aerosol samples from polymerase chain reaction (PCR)-confirmed COVID-  
76 19 cases infected with SARS-CoV-2, including alpha and earlier variants, circulating in a university  
77 campus community using a Gesundheit-II (G-II) exhaled breath sampler[10,11]. We measured  
78 concentrations of SARS-CoV-2 RNA and recovered infectious virus from respiratory swabs, saliva, and  
79 aerosols, analyzed the effectiveness of face masks as source control, and examined the impact of the  
80 alpha variant on aerosol shedding.

## 81 Materials and Methods

82  
83 This study was approved by the University of Maryland Institutional Review Board and the Human  
84 Research Protection Office of the Department of the Navy. Electronically signed informed consent was  
85 obtained and questionnaire data were collected and stored with REDCap[12].  
86

87 We recruited participants with active infection (defined as positive qRT-PCR for SARS-CoV-2 in  
88 respiratory swab or saliva samples) from the University of Maryland College Park campus and  
89 surrounding community through a) daily symptom reporting and weekly pooled saliva testing from a  
90 cohort of 238 volunteers, b) direct recruiting of recently diagnosed cases targeting local clinics and  
91 campus isolation facilities, and c) frequent testing of close contacts of cases for two weeks following last  
92 contact. Recruited cases and close contacts completed online consents and a questionnaire (see  
93 Supplemental Methods) before in-person confirmation of consent and specimen collection at the  
94 University of Maryland School of Public Health. For contacts, we collected a blood specimen for  
95 serology at the first visit and measured oral temperature, blood oxygen saturation (SpO<sub>2</sub>), and collected  
96 a mid-turbinate swab (MTS) from each nostril and a saliva sample, at approximately two-day intervals.  
97

98 Cohort members with a positive saliva sample, recently-diagnosed cases, and contacts with a positive  
99 test during follow-up were invited for viral shedding assessment visits on two days separated by one  
100 day. Venous blood was collected at the first visit; MTS, saliva, phone/tablet swab, and 30-minute G-II  
101 exhaled breath samples were collected at each visit[10,11]. We asked participants to provide paired  
102 breath samples at each visit with the first collected while wearing a face mask and a second without a  
103 mask[13]. We tested the mask brought by the participant and a surgical mask that we provided, and  
104 randomized which was tested at the first and second visit to avoid a systematic order bias. Cases studied  
105 before September 2020 were asked to repeat the alphabet three times within the 30-minute sampling

106 period, as previously described [13]. Subsequent cases were asked to shout “Go Terps” 30 times and  
107 sing “Happy Birthday” loudly three times at 5, 15, and 25 minutes into each 30-minute sampling period.  
108 Participants with more severe symptoms sometimes opted to give only one 30-minute breath sample; for  
109 these participants, sampling without a face mask was given priority.

#### 110 *Symptom evaluation*

111 Symptoms were self-reported and measured on a scale of 0-3 and composite scores were sums of  
112 individual symptom scores for systemic, gastrointestinal, lower respiratory, and upper respiratory  
113 symptoms as previously described[10], see Supplementary Information [SI] for additional details.

#### 114 *Sample preparation*

115 MTS and phone/tablet swabs were eluted in 1 mL of Universal Transport Media (BD). MTS from both  
116 nostrils were combined. G-II coarse and fine aerosol samples were concentrated, resulting in a 1-mL  
117 final sample volume as previously described.[10] One aliquot each of MTS and saliva samples were  
118 kept at 4 °C for immediate qRT-PCR. All other aliquots were stored at -80 °C until further analysis.

#### 119 *Laboratory analyses*

120 Specific laboratory analysis details can be found in the SI. Cohort saliva was processed using the  
121 SalivaDirect method[14]. For all other samples, nucleic acids were extracted with MagMax Pathogen  
122 RNA/DNA Kit (Applied Biosystems) on KingFisher Duo Prime (Thermo Scientific), following  
123 manufacturer protocols specific to sample type. Viral RNA was detected and quantified using the  
124 TaqPath COVID-19 Real Time PCR Assay Multiplex and coinfection of samples was determined using  
125 the TaqMan Array Card (both Thermo Scientific). RNA copy numbers are reported per mL for saliva  
126 and per sample for all other sample types. The limit of detection (LOD) was 75 copies/sample and the  
127 limit of quantification (LOQ) was 250 copies/sample (SI).

128 Viral infectivity was measured by first propagating virus on Vero E6 cells stably expressing TMPRSS2  
129 then transferring the media to A549 cells stably expressing human ACE2 (A549-ACE2). Infected A549-  
130 ACE2 cells were quantified using immunofluorescence staining with anti-SARS-CoV-2 nucleocapsid  
131 antibody (Sino Biological 40143-R004) and Hoechst 33342 (Invitrogen H3570), and imaging with a  
132 Celigo Imaging Cytometer (Nexcelom) (Figures S1, S2). Plasma was analyzed for IgG, IgM, and IgA  
133 antibodies to SARS-CoV-2 using a modified protocol described by Stadlbauer et al., 2020[15]. MTS and  
134 saliva samples were sequenced at the Walter Reed Army Institute for Research or the University of  
135 Maryland Institute for Genome Sciences. SARS-CoV-2 lineages and mutations were determined using  
136 PANGOLIN and Nextstrain tools[16,17].

#### 137 *Statistical analysis*

138 We included analysis of all actively infected cases recruited from the campus and surrounding  
139 community over the course of one year. To ensure comparability of with and without mask samples in  
140 the analysis of mask efficacy, we included only paired same-day samples collected with and without a  
141 face mask from the same person and controlled for numbers of coughs during each sampling session.

142 Data curation, cleaning, analysis, and visualization were performed using R Studio and R (version  
143 4.1.0)[18], with R packages lme4, lme4, and ggplot2[19]. We made group comparison between  
144 seronegative and seropositive cases using two-sample t-test for continuous variables and Fisher’s exact  
145 test for categorical variables. To handle censored observations below the limit of detection, we applied

152 linear mixed-effect models with censored responses[20,21] and included nested random effects of  
153 samples within each case, and replicates within samples. The geometric means and standard deviations  
154 of viral RNA copy numbers for all sample types and the effect of the predictors of viral RNA shedding  
155 were estimated from the model. Deidentified data and code for the accepted manuscript will be made  
156 available on github.  
157

## 158 Results

159  
160 Sixty-one people with active SARS-CoV-2 infection (recent onset and positive PCR for MTS or saliva)  
161 were enrolled in exhaled breath testing: 3 from a weekly saliva testing cohort, 43 from among 55  
162 recently diagnosed COVID-19 cases, and 15 from among 62 contacts of cases followed to detect early  
163 onset of infection (Figure S3). Eight people (13%) with active infection had either IgM or IgG  
164 antibodies to SARS-CoV-2 spike protein at the first breath testing visit and four were unable to give a  
165 venous blood sample.  
166

167 The 57 participants with known serologic status at the time of breath sampling (49 seronegative, 8  
168 seropositive) were enrolled from zero to 12 days post onset of symptoms or first positive test (Table 1,  
169 Figure S4). The seronegative cases included all participants with prior singing experience and alpha  
170 variant infection – there were no other significant differences between seropositive and seronegative  
171 groups including frequency of loss of taste/smell, other symptoms, temperature and oxygen saturation.  
172 All cases were asymptomatic or mild at the time of study. No volunteer was taking antiviral medication  
173 at the time of breath sample collection and no co-infections were identified.  
174

### 175 *Seronegative cases*

176 Among seronegative participants, 4 (8%) were infected with the alpha and none with delta or other  
177 variants associated with increased transmissibility[22] (Table S1). Symptoms tended to be more  
178 pronounced at the first shedding visit and two participants were febrile at the second shedding visit  
179 (Figures S5-S6). Each of the 4 seronegative alpha variant cases had detectable concentrations of viral  
180 RNA in all MTS, saliva, fomite, and aerosol samples (Table 2). Among the remaining seronegative  
181 participants, we detected viral RNA in all MTS, 99% of saliva, 49% of fomite, 19% of coarse-, and 31%  
182 of fine-aerosol samples. The geometric mean concentrations of viral RNA were significantly greater for  
183 all sample types collected from alpha variant cases.  
184

### 185 *Exhaled breath viral RNA from seronegative cases without masks*

186 Viral RNA content of 30-minute breath aerosol samples was similar to the amount of RNA recovered  
187 from participants' mobile phones (Table 2). The frequency of detection of viral RNA in aerosols was  
188 greatest 2-5 days post onset of symptoms or first positive test (Figure S7) but was not a significant  
189 predictor of the quantity of viral RNA in the aerosols (Table 3). Viral RNA in MTS and saliva were  
190 moderately correlated (Figure S8:  $\rho=0.46$ ) but only RNA in MTS was a strong predictor of viral load in  
191 aerosols (Table 3, Figures S9, S10). The quantity of viral RNA in the fine-aerosol fraction was 1.9-fold  
192 (95% confidence interval [CI] 1.2 to 2.9-fold) greater than in the coarse-aerosol fraction (not shown).  
193

### 194 *Effect of alpha variant infection on viral RNA shedding from seronegative cases*

195 Alpha variant infection was associated with significantly greater amounts of viral RNA shedding than  
196 infection with earlier strains and variants. In bivariate analyses of samples collected without masks

(Tables 3 and S3), the alpha variant was associated with significantly greater viral RNA shedding than wild-type and other variants not associated with increased transmissibility. Fine-aerosol shedding remained significantly greater for alpha variant infections (18-fold, 95% CI, 3.4 to 92-fold) after adjusting for the increased viral RNA in MTS and saliva, the number of coughs during sampling sessions, and symptoms (Table 3). We also analyzed the impact of alpha variants on shedding using the larger data set, including samples collected with and without masks. After controlling for the effect of masks and numbers of coughs during sampling, alpha variant infection was associated with a 100-fold (95% CI, 16 to 650-fold) increase in coarse- and a 73-fold (95% CI, 15 to 350-fold) increase in fine-aerosol RNA shedding (Table 3).

#### *Effect of masks on viral RNA shedding from seronegative cases*

We observed statistically significant reductions in aerosol shedding after adjusting for number of coughs during sampling sessions: 77% (95% CI, 51% to 89%) reduction for coarse and 48% (95% CI, 3% to 72%) for fine aerosols (Figure 1). Analysis of the interaction of masks and the alpha variant (Table 3) confirmed that mask performance was not significantly different for alpha variant infections. The types of face masks brought by participants varied and progressed from single-layer homemade and an imported decorative scarf-mask early in the study to homemade and commercial double-layer cloth masks, surgical masks, double masks, and a KN95 over the course of the year (Table S4). We did not observe a significant difference between surgical masks and a composite of the various cloth masks studied (Table S5).

#### *Seropositive cases*

Eight participants had antibodies to SARS-CoV-2 spike protein at the time of breath sample collection. Seropositive cases tended to cough more than seronegative cases (Table 1) but none of the exhaled aerosol samples from seropositive cases had detectable viral RNA (Table S6).

#### *Virus cultures*

Among samples subjected to virus culture, we detected infectious virus (Figure S2) in 50 (68%) of 73 MTS and 20 (32%) of 62 saliva samples from seronegative participants (Figure 2, Table S2a). The RNA concentration associated with a 50% probability of a positive culture was  $7.8 \times 10^5$  for MTS and  $5.2 \times 10^6$  for saliva (Figure S11, Table S7). None of the 75 fine-aerosol samples collected while not wearing face masks were culture-positive. Two (3%) of the 66 fine-aerosol samples collected from participants while wearing face masks were culture-positive, including one from a person infected with the alpha variant 2 days post onset and one from a person with a Nextstrain clade 20G virus 3 days post onset. Fomite and coarse-aerosol samples subjected to culture were negative.

## Discussion

Alpha variant infection yielded one to two orders of magnitude more viral RNA in exhaled breath when compared with earlier strains and variants not associated with increased transmissibility. Our observation of increased aerosol shedding, even after controlling for the increased amounts of viral RNA in the nose and mouth, suggests that evolutionary pressure is selecting for SARS-CoV-2 capable of more efficient airborne transmission.

We recovered infectious virus from two exhaled breath fine-aerosol samples, approximately two-thirds of MTS, and one-third of saliva samples. Logistic regression analysis of the MTS and saliva samples suggests that there is a small but measurable probability that each RNA copy represents an infectious

242 viral particle consistent with previous dose-response models of infectious viruses[23]. The probability of  
243 detecting infectious virus in our cell culture system may be as high as  $10^{-4}$  per RNA copy in saliva  
244 samples with  $10^2$  copies. We recovered infectious virus from one of the two fine-aerosol samples  
245 with  $>10^4$  RNA copies per sample, where the estimated probability of a positive culture was 8% per  
246 sample, based on the regression model. The other culture-positive aerosol sample was one of 98 aerosol  
247 samples below the 75-copy limit of detection for RNA. This observation is consistent with a previous  
248 report of infectious SARS-CoV-2 in an aerosol sample with very low RNA copy numbers[5], and may  
249 suggest that virus particles in respiratory aerosols contain fewer defective virions than MTS, or that the  
250 fluid is less likely to interfere with viral cell attachment and entry than are nasal secretions and saliva. It  
251 is likely that human airway epithelium is more susceptible to infection than laboratory cell cultures[24].  
252

253 The assorted face masks used by the study volunteers produced significant, albeit modest, reductions in  
254 the amount of viral RNA in exhaled breath, supporting their use as source control. Consistent with  
255 previous studies of influenza, SARS-CoV-2 viral RNA was shed more abundantly in fine than coarse  
256 aerosol and masks were more effective at blocking release of coarse aerosol[10,13,25,26]. The  
257 effectiveness of face masks for blocking release of fine aerosol (1.9-fold) was similar to the  
258 effectiveness we previously reported for influenza (2.8-fold). However, the 4.3-fold (or 77%) reduction  
259 in coarse aerosol was significantly less than the 25-fold reduction previously observed for influenza  
260 shedding[13]. This discrepancy likely arose because the more vigorous and extended vocalizations in the  
261 current study would be expected to maximize leakage around loose-fitting face masks. Face masks  
262 worked equally well for containing alpha variant and “wild-type” aerosol shedding.  
263

264 Viral RNA aerosol collected from 22 COVID-19 patients in Singapore using a G-II measured similar  
265 RNA copy numbers and overall rates of positive breath samples (59% versus 51% here) during singing  
266 and loud talking as observed here[27]. A majority (68%) of the cases studied in Singapore were infected  
267 by variants associated with increased transmissibility, while 18% of infections were not variants of  
268 concern or interest, and each case was sampled on only one day. By comparison, our sample included  
269 more “wild-type” infections and sampling days per person allowing analysis of the impact of variants on  
270 shedding. One delta variant was studied in Singapore and none in this study. The shedding rates detected  
271 using the G-II in both studies, however, were lower than those reported by Ma et al. using a sampler that  
272 requires subjects to blow through a narrow straw[28]. Ma et al. and our data are in agreement that  
273 among persons infected with “wild-type” strains, a minority (26% and 31%, respectively) shed  
274 detectable levels of viral RNA into aerosols. However, our data on alpha variant infections and the data  
275 from Singapore suggest that this is changing and most cases may now be shedding viral aerosols more  
276 frequently. We have yet to enroll cases with the delta variant and study them using the Maryland  
277 protocol to test the expectation, based on our current findings, that delta will be associated with an  
278 additional large increase in aerosol shedding.  
279

280 Our study had several limitations. Although we attempted to identify and test cases early through weekly  
281 testing of a cohort and intensive follow-up of close contacts, most cases were still studied several days  
282 after onset of symptoms or first positive test. This likely resulted in missing the most contagious  
283 period[29,30]. Furthermore, all cases were mild at the time of testing and only two went on to have  
284 moderate severity and require hospitalization. As a result, our data may not represent the full spectrum  
285 of shedding. The types of face masks worn by participants changed over the course of the study, as did  
286 the quality of surgical masks that we could purchase. Therefore, we cannot report on the efficacy of  
287 specific loose-fitting masks. This work does, however, provide information on the average amount of

288 source control provided by community masking. Finally, logistical considerations required that we  
289 freeze samples between collection and culture, with potential loss of infectiousness, especially for dilute  
290 aerosol specimens.

291  
292 Overall, our results demonstrate that people with mild or asymptomatic SARS-CoV-2 infections  
293 released infectious aerosols in their exhaled breath. Face masks provided significant source control  
294 suggesting that community-wide masking even with loose-fitting masks can reduce viral aerosols in  
295 indoor air by half, making a significant contribution to reducing the spread of COVID-19. Our data also  
296 suggest that the virus is evolving toward more effective dissemination through aerosols and demonstrate  
297 that infectious virus can escape from loose-fitting masks. With the dominance of newer, more  
298 contagious variants than those we studied, increased attention to improved ventilation, filtration, air  
299 sanitation, and use of high-quality tight-fitting face masks or respirators (e.g., ASTM F3502-21 face-  
300 coverings or NIOSH approved N95 filtering face-piece and elastomeric respirators) for respiratory  
301 protection will be increasingly important for controlling the pandemic. This will be especially true  
302 where vaccination rates are low, vaccine is not available, and for people with poor immune responses or  
303 waning immunity. Therefore, our data support community mask mandates and tight-fitting masks or  
304 respirators for workers in healthcare but also in all workplaces where people are sharing indoor air or  
305 have frequent public contact.

### 309 Acknowledgements

310 We thank Dr. Jacques Ravel, Dr. Luke Tallon, and the Institute of Genome Sciences at the University of  
311 Maryland School of Medicine for performing deep sequencing of SARS-CoV-2 samples. We also thank  
312 Dr. Jamal Fadul and his clinic in College Park, Maryland, for assistance in recruiting study participants.

### 313 Disclaimers and Funding

314 Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its  
315 presentation and/or publication. The investigators have adhered to the policies for protection of human  
316 subjects as prescribed in AR 70–25. The View(s) expressed are those of the authors and do not  
317 necessarily reflect the official views of the Department of Health and Human Services, the Departments  
318 of the Army, Navy or Air Force, the Department of Defense, or the U.S. Government. The findings and  
319 conclusions in this report are those of the authors and do not necessarily represent the official position or  
320 policy of these agencies and no official endorsement should be inferred.

321  
322 This work was supported by Prometheus-UMD, sponsored by the Defense Advanced Research Projects  
323 Agency (DARPA) BTO under the auspices of Col. Matthew Hepburn through agreement N66001-18-2-  
324 4015. This work was also supported by the National Institute of Allergy and Infectious Diseases Centers  
325 of Excellence for Influenza Research and Surveillance (CEIRS), Grant Number HHSN272201400008C,  
326 the Centers for Disease Control and Prevention, Contract Number 200-2020-09528. The findings and  
327 conclusions in this report are those of the authors and do not necessarily represent the official position or  
328 policy of these funding agencies and no official endorsement should be inferred.



330 This work was also supported by a grant from the Bill & Melinda Gates Foundation, and a generous gift  
331 from The Flu Lab (<https://theflulab.org>). The funders had no role in study design, data collection,  
332 analysis, decision to publish, or preparation of the manuscript.  
333  
334

## References

1. World Health Organization. Coronavirus disease (COVID-19): How is it transmitted? 2021. Available at: <https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-how-is-it-transmitted>. Accessed 31 May 2021.
2. CDC. Scientific Brief: SARS-CoV-2 Transmission. 2021. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html>. Accessed 8 May 2021.
3. Morawska L, Milton DK. It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis* **2020**; 71:2311–2313.
4. Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. *Lancet* **2021**; 397:1603–1605.
5. Lednicky JA, Lauzardo M, Fan ZH, et al. Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. *Int J Infect Dis* **2020**; 100:476–482.
6. Lednicky JA, Lauzardo M, Alam MDM, et al. Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness. *Infectious Diseases (except HIV/AIDS)*, 2021. Available at: <http://medrxiv.org/lookup/doi/10.1101/2021.01.12.21249603>. Accessed 1 February 2021.
7. Chia PY, Coleman KK, Tan YK, et al. Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. *Nat Commun* **2020**; 11:2800.
8. Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. *Nature* **2020**; 582:557–560.
9. Miller SL, Nazaroff WW, Jimenez JL, et al. Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event. *Indoor Air* **2020**;
10. Yan J, Grantham M, Pantelic J, et al. Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community. *Proc Natl Acad Sci USA* **2018**; 115:1081–1086.
11. McDevitt JJ, Koutrakis P, Ferguson ST, et al. Development and Performance Evaluation of an Exhaled-Breath Bioaerosol Collector for Influenza Virus. *Aerosol Sci Technol* **2013**; 47:444–451.
12. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *Journal of Biomedical Informatics* **2019**; 95:103208.
13. Milton DK, Fabian MP, Cowling BJ, Grantham ML, McDevitt JJ. Influenza virus aerosols in human exhaled breath: particle size, culturability, and effect of surgical masks. *PLoS Pathog* **2013**; 9:e1003205.
14. Vogels CBF, Brackney D, Wang J, et al. SalivaDirect: Simple and sensitive molecular diagnostic test for SARS-CoV-2 surveillance. *Infectious Diseases (except HIV/AIDS)*, 2020. Available at: <http://medrxiv.org/lookup/doi/10.1101/2020.08.03.20167791>. Accessed 17 August 2020.

- 369 15. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed  
370 Protocol for a Serological Assay, Antigen Production, and Test Setup. *Current Protocols in*  
371 *Microbiology* **2020**; 57:e100.
- 372 16. O'Toole Á, Hill V, McCrone JT, Scher E, Rambaut A. cov-lineages/pangolin. CoV-lineages, 2021.  
373 Available at: <https://github.com/cov-lineages/pangolin>. Accessed 15 July 2021.
- 374 17. Trevor Bedford, Richard Nehe, James Hadfield, et al. Nextstrain SARS-CoV-2 resources. 2020.  
375 Available at: <https://nextstrain.org/sars-cov-2/>. Accessed 29 July 2021.
- 376 18. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R  
377 Foundation for Statistical Computing, 2021. Available at: <https://www.R-project.org/>.
- 378 19. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2nd ed. Springer International  
379 Publishing, 2016. Available at: <https://www.springer.com/gp/book/9783319242750>. Accessed 11  
380 June 2020.
- 381 20. Vaida F, Fitzgerald AP, DeGruttola V. Efficient Hybrid EM for Linear and Nonlinear Mixed Effects  
382 Models with Censored Response. *Comput Stat Data Anal* **2007**; 51:5718–5730.
- 383 21. Vaida F, Liu L. Fast Implementation for Normal Mixed Effects Models With Censored Response. *J*  
384 *Comput Graph Stat* **2009**; 18:797–817.
- 385 22. CDC. SARS-CoV-2 Variant Classifications and Definitions. 2021. Available at:  
386 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>. Accessed 12 July 2021.
- 387 23. Haas CN. Estimation of risk due to low doses of microorganisms: a comparison of alternative  
388 methodologies. *Am J Epidemiol* **1983**; 118:573–582.
- 389 24. Pohl MO, Busnadiego I, Kufner V, et al. SARS-CoV-2 variants reveal features critical for  
390 replication in primary human cells. *PLoS Biol* **2021**; 19:e3001006.
- 391 25. Lindsley WG, Noti JD, Blachere FM, et al. Viable influenza A virus in airborne particles from  
392 human coughs. *J Occup Environ Hyg* **2015**; 12:107–113.
- 393 26. Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy  
394 of face masks. *Nat Med* **2020**; 26:676–680.
- 395 27. Coleman KK, Tay DJW, Tan KS, et al. Viral Load of SARS-CoV-2 in Respiratory Aerosols Emitted  
396 by COVID-19 Patients while Breathing, Talking, and Singing. *medRxiv* **2021**;  
397 :2021.07.15.21260561.
- 398 28. Ma J, Qi X, Chen H, et al. COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per  
399 hour. *Clin Infect Dis* **2020**; Available at: [https://academic.oup.com/cid/advance-](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1283/5898624)  
400 [article/doi/10.1093/cid/ciaa1283/5898624](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1283/5898624).
- 401 29. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-  
402 19. *Nature Medicine* **2020**; 26:672–675.

- 403 30. Yang Q, Saldi TK, Gonzales PK, et al. Just 2% of SARS-CoV-2-positive individuals carry 90% of  
404 the virus circulating in communities. Proc Natl Acad Sci U S A **2021**; 118:e2104547118.

405

406 **Tables**

407

408 **Table 1. Characteristics of the study population**

	Antibody negative	Antibody positive	All with serologic tests	<i>P-value</i> <sup>a</sup>
Number of participants	49	8	57	-
Number of exhaled breath sample visits <sup>b</sup>	78	15	93	-
Female, N (%)	18 (37)	2 (25)	20 (35)	0.70
Age, mean years ± SD	23.7 ± 9.5	24.9 ± 8.4	23.8 ± 9.3	0.73
Age group, N (%)				-
<18	1 (2)	0 (0)	1 (2)	
18-45	45 (92)	8 (100)	53 (93)	
>45	3 (6)	0 (0)	3 (5)	
White, N (%)	40 (82)	5 (62)	45 (79)	0.16
BMI, mean ± SD	24.6 ± 4.5	27.3 ± 4.8	25 ± 4.6	0.12
Chronic respiratory illness <sup>c</sup> N (%)	12 (24)	1 (12)	13 (23)	0.67
Ever smoker N (%)	2 (4)	1 (12)	3 (5)	0.37
Has taken singing lessons/part of a choir N (%)	4 (8)	0 (0)	4 (7)	-
Alpha Variant N (%)	4 (8)	0 (0)	4(7)	-
Days post onset <sup>d</sup> mean ± SD (range)	3.8 ± 2.1 (Day 1 to 10)	5.9 ± 3.8 (Day 0 to 12)	4.1 ± 2.5 (Day 0 to 12)	0.18
Coughs per 30 min, mean ± SD (range)	1 ± 3 (0-17)	3 ± 8 (0-24)	1 ± 4 (0-24)	0.098
Loss of taste/smell N (%)	13 (27)	4 (50)	17 (30)	0.22
Median upper respiratory symptoms (IQR) <sup>e</sup>	2 (1 - 3)	3 (1.5 - 4)	2 (1 - 3)	0.17
Median lower respiratory symptoms (IQR)	0 (0 - 1.2)	0 (0 - 1)	0 (0 - 1)	0.82
Median systemic symptoms (IQR)	1 (0 - 3)	1 (0 - 2.5)	1 (0 - 3)	0.60
Median gastrointestinal symptoms (IQR)	0 (0 - 1)	0 (0)	0 (0-1)	0.36
Temperature, mean Celsius ± SD	37.2 ± 0.4	37.2 ± 0.2	37.2 ± 0.3	0.80
Oxygen saturation (SpO <sub>2</sub> ), mean ± SD	97.9 ± 1	97.5 ± 1.1	97.8 ± 1	0.25

409 BMI, Body mass index; IQR, Interquartile range;

- 410 <sup>a</sup> Group comparisons were made between antibody negative and positive cases using two-sample t-test for continuous variables and  
411 Fisher's exact test for categorical variables.
- 412 <sup>b</sup> 57 volunteers provided breath samples and sera at the initial shedding assessment visit; 34 of them provided exhaled breath samples  
413 at the 2<sup>nd</sup> shedding assessment visit approximately 2 days later; four volunteers who did not provide sera at the first visit were  
414 excluded.
- 415 <sup>c</sup> Chronic respiratory illness = volunteers with any Chronic obstructive pulmonary disease, Asthma, Other lung diseases.
- 416 <sup>d</sup> Days since start of symptoms or first positive test if asymptomatic or presymptomatic to first breath sample; 3 subjects reported no  
417 symptoms.
- 418 <sup>e</sup> Symptoms at the time of each sample collection visit. Sixteen symptoms were rated from 0 to 3 with a maximum possible composite  
419 score of 15 for upper respiratory, 9 for lower respiratory, 12 for systemic symptoms and 12 for gastrointestinal symptoms.

Table 2. Viral RNA from cases seronegative for SARS-CoV-2 antibodies at the first assessment

Sample Type	Variant	Case <sup>a</sup>	Cases with $\geq 1$ positive sample <sup>b</sup>		Samples	Positive Samples <sup>c</sup>		GM (95% CI) <sup>d</sup>	Maximum RNA copies <sup>e</sup>
			$\geq \text{LOD}$	$\geq \text{LOQ}$		$\geq \text{LOD}$	$\geq \text{LOQ}$		
Mid-turbinate swab	Alpha	4	4 (100)	4 (100)	6	6 (100)	6 (100)	$3.8 \times 10^8$ ( $3.3 \times 10^8, 4.4 \times 10^8$ )	$2.9 \times 10^9$
	Other	45	45 (100)	45 (100)	74	74 (100)	73 (99)	$3.8 \times 10^6$ ( $1.4 \times 10^6, 1.0 \times 10^7$ )	$5.1 \times 10^9$
Saliva	Alpha	4	4 (100)	4 (100)	6	6 (100)	6 (100)	$1.9 \times 10^7$ ( $2.7 \times 10^6, 1.3 \times 10^8$ )	$5.2 \times 10^8$
	Other	45	44 (98)	44 (98)	74	73 (99)	70 (95)	$2.1 \times 10^5$ ( $8.1 \times 10^4, 5.4 \times 10^5$ )	$3.9 \times 10^8$
Fomite	Alpha	4	4 (100)	4 (100)	6	6 (100)	4 (67)	560 (530, 590)	$1.7 \times 10^4$
	Other	45	28 (62)	14 (31)	74	36 (49)	17 (23)	46 (17, 120)	$1.2 \times 10^6$
Coarse (>5 $\mu\text{m}$ ) Aerosol	Alpha	4	4 (100)	2 (50)	6	6 (100)	3 (50)	140 (28, 730)	$5.1 \times 10^4$
	Other	45	11 (24)	5 (11)	72	14 (19)	5 (7)	7 (3.2, 15)	$2.6 \times 10^4$
Fine ( $\leq 5 \mu\text{m}$ ) Aerosol	Alpha	4	4 (100)	3 (75)	6	6 (100)	4 (67)	580 (450, 740)	$5.4 \times 10^4$
	Other	45	18 (40)	8 (18)	72	22 (31)	9 (12)	18 (9.1, 34)	$2.8 \times 10^3$

<sup>a</sup> Participants with a mid-turbinate or saliva samples positive for SARS-CoV-2 viral RNA by qRT-PCR and seronegative for SARS-CoV-2 spike protein antibody at enrollment and who provided at least one 30-minute sample of exhaled breath.

<sup>b</sup> Number of participants with at least one sample  $\geq$  limit of detection (LOD) or  $\geq$  limit of quantification (LOQ) (Supplementary).

<sup>c</sup> Samples positive and  $\geq \text{LOD}$  had at least one replicate with confirmed amplification after inspection and quality control (LOD  $\sim 75$  RNA copies with 95% probability of detection) and  $\geq \text{LOQ}$  if the mean of replicate assays was  $\geq 250$  RNA copies.

<sup>d</sup> GM = geometric mean. The GMs were computed, accounting for samples below the LOD, using a linear mixed-effects model for censored responses (R Project LMEC package) using data for all samples of each sample type with nested random effects of samples within study participant.

<sup>e</sup> The largest quantity of RNA copies detected based on the mean of replicates qRT-PCR aliquots.

Table 3. Predictors of viral RNA shedding among seronegative participants

	Coarse Aerosol (>5 µm)			Fine Aerosol (≤5 µm)		
	Without Face Mask N=49, n=78 <sup>a</sup>		Paired ± Mask N=46, n = 69	Without Face Mask N=49, n=78		Paired ± Mask N=46, n = 69
	Unadjusted	Adjusted <sup>b</sup>	Estimate <sup>c</sup>	Unadjusted	Adjusted	Estimate
<b>Alpha Variant</b>	67 (6.7, 660)	3.6 (0.35, 36)	100 (16, 650)	43 (6.6, 280)	18 (3.4, 92)	73 (15, 350)
<b>Face mask</b>	-	-	0.23 (0.11, 0.49)	-	-	0.52 (0.28, 0.97)
<b>Age</b>	1.4 (0.44, 4.4)	-	-	1.7 (0.74, 3.7)	1.7 (1, 2.8)	-
<b>Day post onset<sup>d</sup></b>	0.79 (0.53, 1.2)	-	-	0.97 (0.76, 1.2)	-	-
<b>Log mid-turbinate swab</b>	480 (40, 5700)	36 (3.5, 370)	-	13 (4.3, 42)	7.3 (2.5, 21)	-
<b>Log saliva</b>	4.6 (1.4, 15)	1.5 (0.55, 4.3)	-	2.8 (1.2, 6.5)	0.96 (0.47, 2)	-
<b>Number of coughs</b>	1.2 (0.92, 1.5)	1.2 (1, 1.5)	1 (0.93, 1.2)	1.2 (0.96, 1.5)	1.2 (1, 1.3)	1.1 (1, 1.3)
<b>Upper respiratory symptoms</b>	2.4 (0.91, 6.1)	-	-	1.7 (0.83, 3.6)	0.75 (0.44, 1.3)	-
<b>Lower respiratory symptoms</b>	0.99 (0.36, 2.7)	0.4 (0.13, 1.2)	-	0.64 (0.3, 1.4)	-	-
<b>Gastrointestinal symptoms</b>	2.3 (1.1, 5.2)	1.2 (0.55, 2.4)	-	1.7 (0.94, 3.2)	1 (0.61, 1.7)	-
<b>Systemic symptoms</b>	5.7 (2.5, 13)	2.4 (0.97, 6.1)	-	2.1 (1.1, 4)	1.1 (0.59, 2)	-
<b>Alpha Variant x Face mask</b>	-	-	0.62 (0.15, 2.7)	-	-	0.7 (0.2, 2.4)

Effect estimates and their 95% confidence intervals are shown as the ratio of RNA copy number of samples: with alpha variant to without alpha variant, with mask to without mask, or as the fold-increase in RNA copy number for a 10-year increase in age, 1-day increase in day post-symptom onset, and an interquartile range change in symptom scores, mid-turbinate swab and saliva RNA copy number. All



analyses were controlled for random effects of subject and sample nested within subjects and for censoring by the limit of detection using a linear mixed-effects model for censored responses (R Project lme4-package).


<sup>a</sup> N = Number of participants, n = number of samples for without face mask analysis and number of pairs of same day with and without face masks samples for paired analysis of the effect of face masks.

<sup>b</sup> The adjusted estimates accounted for potential covariates resulting in greater than 10% change in the estimates of the main exposure variable – “Alpha variant”


<sup>c</sup> The effect of mask on samples adjusted for Alpha variant and number of coughs counted during sample collection

<sup>d</sup> Days since start of symptoms or first positive test if asymptomatic or presymptomatic to breath sample; 2 subjects had no symptoms

## FIGURES



**Figure 1.** Viral RNA shedding in paired with and without face mask samples. Viral RNA measured during 69 same-day paired sampling events with and without mask from 46 seronegative cases. Samples with no detected viral RNA were assigned a copy number value of one. Exhaled breath aerosols were obtained in 30-minute sampling durations. “+mask” = sample collected while wearing a face mask. MTS = mid-turbinate swab, Fomite = swab of participant’s mobile phone.



**Figure 2.** Viral RNA content and culture results of samples from all sampling events for seronegative cases. Samples with no detected viral RNA were assigned a copy number value of one. Exhaled breath aerosols were obtained during 30-minute sampling events and included unpaired with and without face mask samples. Five fine aerosol samples with face mask and three fomite samples were not available for culture. A subset of MTS, saliva, and coarse aerosol samples were subjected to culture. MTS = mid-turbinate swab, Fomite = swab of participant's mobile phone.